Human Genome Sciences Announces Positive 76-Week Results Of Phase 2 Clinical Trial Of

New cases in Pous 2064, HIV = 175, AIDS = 26, Death = 2. HIV rate is very high in Housewives than sex workers in Nepal ! ! ! HIV status in Nepal till 2005: Total Adult=70000, Adult Prevalence (15-49)=0.55%, Number of Women (15-49) LWHA=15,310 (22%), HIV Prevalence rate in IDUs=32.7%, HIV prevalence rate in sex worker=3.8%, HIV prevalence rate in client of SW=2.1%. The latest U.N. report shows that 65 million people have been infected with HIV since it was first identified 25 years ago. Twenty five million people have died of AIDS.

Welcome to the xenoMED, an online Medical Community where Academically sound, Professionally conscious and Socially responsible Medical Students, Doctors & Health Professionals interact with each other globally.

Medicine is the only profession that incessantly tries to destroy its own existence. Howsoever you may be associated with basic and/or clinical medicine - student or professor, physician or surgeon, undergraduate or postgraduate - this is your place to share your knowledge, and learn more. Just get the message across!

You are currently viewing our communiy as a guest which gives you limited access to view most discussions and access our other features. By joining our free community you will have access to post topics, communicate privately with other members (PM), respond to polls, upload content and access many other special features. Registration is fast, simple and absolutely free so please, Join Our Medical Cummunity Today!

If you have any problems with the registration process or your account login, please contact us.

		xenoMED > News Room > Health News > Medical News Today
Human Genome Sciences Announces Positive 76-Week Results Of Phase 2 Clinical Trial Of

(#1 (permalink))

Angel is Offline

xenoMED

Posts: 76,181

Images: 316

Blog Entries: 16

Thanks: 104

Thanked 26,784 Times in 26,626 Posts

Join Date: Oct 2005

Human Genome Sciences Announces Positive 76-Week Results Of Phase 2 Clinical Trial Of - 15-11-2006, 01:12 AM

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced today that the 76-week results of a Phase 2 clinical trial demonstrated that LymphoStat-B(TM) (belimumab) reduced disease activity in patients with serologically active systemic lupus erythematosus (SLE), exhibited durable biological activity, and appeared safe and well tolerated. [click link for full article]

More...

Angel
xenoMED | NDR
“Nothing brings me more happiness than helping people in the society. It is a goal and an essential part of my life - a kind of destiny.”

« Wal-Mart Experiences Higher Online Prescription Drug Sales, Refills After Introductio | GSA Confers 2006 M. Powell Lawton Award To University Of Washington's Teri »

Thread Tools	Search this Thread
Show Printable Version Email this Page	Search this Thread: Advanced Search
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Trackbacks are On Pingbacks are On Refbacks are On

Similar Threads
Thread	Thread Starter	Forum	Replies	Last Post
546 QA Biochemistry Test	Oak	Step I	1	30-10-2007 12:23 AM
Targacept Announces Positive Results Of Phase II Clinical Trial In Major Depression	Angel	Medical News Today	0	10-11-2006 01:13 AM
Human Genome Sciences Reports Interim Results Of Phase 1b Clinical Trial Of HGS-ETR1	Angel	Medical News Today	0	09-11-2006 01:20 AM
Human Genome Sciences Reports Positive Interim Results Of Phase 2 Trials Of Albuferon	Angel	Medical News Today	0	01-11-2006 01:01 AM

Hosted and Maintained by: